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ABSTRACT 
 Correct diagnostic classification of kidney tumors is critical to providing accurate prognostic 
information and enabling potential precision medicine opportunities, however this often requires 
assessing numerous clinical biomarkers by multiple approaches that are both time- and cost-intensive. 
Here, we sought to determine whether a multiplex-PCR based RNA sequencing (mxRNAseq) panel 
targeted to kidney cancer relevant genes could facilitate diagnosis of both common and rare kidney 
tumors as well as inform on prognosis and therapeutic targets. Through assessment of over 146 clinical 
formalin fixed paraffin embedded (FFPE) samples using a 122 target gene mxRNAseq panel, we 
demonstrate that this approach enables robust classification of common kidney tumor subtypes using both 
supervised and unsupervised techniques. To facilitate precision medicine opportunities, we demonstrate 
that inclusion of cell-cycle related genes enables the calculation of a previously described 31-gene cell-
cycle proliferation progression (CCP) score, while immune related genes enables identification of 
immune “hot” and “cold” tumors. Taken together, these results support the feasibility and broad potential 
applicability of targeted mxRNAseq for kidney tumor diagnosis, classification, prognosis and therapeutic 
prediction.    
INTRODUCTION 
An emerging management strategy for kidney and other tumors is precision medicine – 
targeting interventions to specific molecular properties. However, such a strategy requires 
accurate assays for all relevant biomarkers. In some tumors this is relatively straightforward – 
management of many colon cancers has been revolutionized by the use of a few driving markers 
to manage care (e.g. KRAS mutations and microsatellite stability status1). However, in kidney 
tumors, such management is made more difficult by the wide variety of subtypes, and the 
morphologic overlap that often requires extensive immunohistochemistry (IHC), fluorescence in 
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situ hybridization (FISH), and/or DNA sequencing for complete subtyping. This heterogeneity 
also complicates the development of broadly applicable prognostic and predictive assays.   
IHC remains the gold standard for measuring protein markers, as it measures the actual 
expressed protein, verses upstream RNA expression or DNA variants that may not impact the 
actual phenotype. Correct subclassification of kidney tumors often requires a battery of 
immunostains2, which makes accurate diagnosis manually intensive and costly. RNA based 
assays may simplify kidney cancer subtyping – if it can be demonstrated that RNA expression is 
a true proxy for protein levels and the loss of spatial expression information and expression 
patterns does not compromise accuracy. Recently, RNAseq has proven to be a method of choice 
for high-throughput RNA analysis. Most RNAseq analyses involve counting transcripts mapped 
to the reference genome, however RNAseq data can also be used to identify mutations in exonic 
regions if probes are designed to capture such regions.3 
Most RNAseq uses a transcriptomics approach, measuring all transcribed mRNA, 
typically by selecting for mRNA poly-A tails, or by using capture probes for exonic regions.4  
This requires a relatively large amount of sequencing capacity to be able to gain a large dynamic 
range but provides data about a sample’s entire transcriptional activity. Unfortunately, such 
approaches are not compatible with RNA isolated from routine FFPE tissues, as it is degraded to 
formalin induced crosslinking. Importantly, FFPE material is available for essentially all patients 
with kidney cancer, after fine needle aspiration, kidney biopsy, partial nephrectomy, 
nephrectomy, or biopsy of metastatic lesions. Likewise, although capture based RNAseq largely 
alleviates issues with poly-A selection and reverse transcription, if often requires hundreds of 
nanograms to microgram quantities of RNA4, which are not available from routine biopsy or fine 
needle aspiration samples.4,5  
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Typical clinical analysis will only focus on a known subset of targets validated for 
analysis – all other protein biomarkers or transcripts are irrelevant and wasteful if the cost is too 
high. One technology enabling sequencing of only targeted regions is multiplexed PCR (after 
reverse transcription for RNA assessment). Sequencing libraries are prepared by first amplifying 
only the targets of interest using specific primers, then sequencing the products, and counting 
reads mapped to genome as with conventional RNAseq. Such a solution enables sequencing 
more samples/patients at a lower cost as well as lower input requirements by focusing on targets 
of interest.  In addition, multiplex-PCR based  amplicon sequencing can be used with smaller 
and more degraded nucleic acids6 than conventional poly-A selection7, as reverse transcription is 
primed using random primers and mRNA specificity is achieved using highly sensitive PCR with 
exon-spanning primers. This enables the use of smaller biopsies for clinical or prospective 
research use and allows for retrospective studies on time and chemically degraded samples. 
In this thesis, I describe how a custom target multiplex RNA sequencing panel 
(mxRNAseq) developed by the Tomlins Lab can be used to characterize features of kidney 
cancers. I focus primarily on two features in which high-throughput molecular interrogation 
provides particular value: Subtyping using multiple expression targets, and assessment of 
proliferation as a potential prognostic feature via a “cell-cycle progression” gene expression 
module. Additionally, I discuss whether inclusion of many targets may provide strategies for the 
better management of Kidney cancers that currently go unclassified by typical means. 
We focused on the ability to classify four common types of kidney tumors based off 
availability in our dataset, the presence of reference data in The Cancer Genome Atlas project, 
and the frequent use of immunohistochemistry to resolve this common differential diagnosis: 
Clear Cell Renal Cell Carcinomas (RCC), Chromophobe RCC, Papillary RCC, and Urothelial 
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Carcinomas.  Classification of these types is typically performed using IHC of six targets: TP63, 
PAX8, CA9, KRT7, KIT, and AMACR. How each of these markers contribute to classification 
is shown in Figure 1. TP63, a key marker of urothelial differentiation8, and PAX8, a PAX family 
transcription factor regulating organogenesis during fetal development5), are used primarily as 
markers differentiating Urothelial Carcinomas from RCCs. Within RCCs, Carbonic Anhydrase 
IX (CA9), a carbonic anhydrase expressed in hypoxic environments serves as a strong marker for 
Clear Cell RCC.10,11  KIT, a protooncogenic stem cell factor12,13, is a strong marker for 
Chromophobe RCC.  Cytokerin KRT7/CK7 is also used to differentiate Chromophobe and 
Papillary RCCs from Clear Cell RCC.2 
Figure 1: A summary of markers used to classify kidney tumors subtypes discussed. Red 
represents presence of protein expression, blue represents absence, and grey represents equivocal 
for a particular subtype.  
 Beyond classification, high-throughput multi-target assays also present the opportunity 
for summary signatures that can capture the behavior of many targets belonging to a larger 
biological process. One example of such a signature is the Cell Cycle Progression (CCP) score, a 
signature averaging expression of 31 cell cycle related genes, originally validated and 
commercialized for prostate cancer.14,15  Our group previously described3 efforts to port this 
signature to a mxRNAseq targeted panel for prostate cancer. Given the near universal relevance 
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of cell cycle/proliferation to molecular oncology (with high proliferation being associated with 
more aggressive disease16), we included these targets on our separate kidney panel to determine 
the feasibility of characterizing cell cycle/proliferation in kidney tumors.  
 Here I describe development and validation of a targeted multiplex RNAseq panel 
capable of assaying both markers relevant for kidney cancer subtyping, and for interrogating 
larger biological events.   
METHODS 
Panel Design and Sequencing 
 Tomlins Lab members identified relevant expression targets from internal and external 
comprehensive evaluation efforts, and designed a custom Ampliseq mxRNAseq panel using  Ion 
AmpliSeq Designer (Thermo Fisher Scientific, Waltham MA.). The panel consisted of 15 
housekeeping genes, and 122 total target genes.  Lab members prepared RNA sequencing 
libraries using the Ion Ampliseq RNA Library kit, and sequenced samples on Ion Torrent Proton 
or Ion Torrent S5 sequencers as described.3 
Patient Cohort 
Routine FFPE tissues were obtained from the University of Michigan Department of 
Pathology Tissue Archive with Institutional Review Board (IRB) approval. Diagnostic 
hematoxylin and eosin–stained slides were reviewed by board-certified anatomic pathologists 
with areas for microdissection/punching indicated as necessary. For each specimen, 1-3 1mm 
punches or 3-10 × 10μm FFPE sections were cut from representative blocks, using 
macrodissection with a scalpel as needed to enrich the tumor content. DNA and RNA were 
isolated and quantified using the Qiagen AllPrep FFPE DNA/RNA Kit (Qiagen, Valencia, CA) 
and the Qubit 2.0 fluorometer (Life Technologies), respectively, as described.3 
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Data Processing 
Torrent suite version 5.04 was used to process raw sequencing data. End to end read 
counts for each panel target were obtained from the Torrent Suite Coverage Analysis plugin 
version 5.0.4.0. All downstream analyses were conducted using R 3.4.1 and Python 3.7.0. All 
statistical models were implemented using the Scikit-learn package17 version 0.20.0.  
Prior to normalization, sample and target gene amplicon quality was assessed to eliminate 
technical artifacts. Samples were only included in downstream analyses if they had at least 
500,000 mapped reads, with at least 60% being end to end. Target gene amplicons were only 
included if they had at least 200 reads in at least 2 samples or more than 1000 reads in at least 
one sample. To ensure robust normalization, performance of all housekeeping genes included on 
the panel was assessed prior to normalization. Only housekeeping genes with median reads 
between 50,00-100,000 reads were averaged for normalization. 
Raw read counts were normalized as previously described.3 Briefly, log2 transformed 
read counts were divided by the geometric mean of the included housekeeping genes. For more 
intuitive plotting, each sample was then scaled by its median for plotting purposes only.  
Data from The Cancer Genome Atlas’ Clear Cell RCC, Chromophobe RCC, Papillary 
RCC, and Urothelial Carcinoma studies18–21 was also included to increase sample size for model 
training. RSEM normalized RNAseq data was downloaded from cBioPortal.22,23 TCGA 
transcriptome RNAseq data was filtered to only include targets included on the targeted 
mxRNAseq panel.  
To ensure analysis comparability, both the TCGA and mxRNAseq datasets were centered 
and scaled according to their mean and standard deviation to ensure a unit mean and variance. 
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Since the TCGA data was used for model training, all data was scaled and centered only 
according to the properties of the training data. Homogenization was confirmed using principal 
component analysis and hierarchical clustering (Figure 2).  
 
Figure 2: Homogenization of TCGA and mxRNAseq data. Panel A: Merged heatmap of 
mxRNAseq and TCGA data for available subtypes. B+C: Principal component analysis(PCA) of 
the merged dataset both combined(B) and separated(C).  
 
Subtype Identifying Models  
We used the Scikit-learn17 package to train statistical models to classify kidney cancer 
subtypes. To ensure model generalization, we trained the model on 75% of the TCGA cohorts, 
and validated on the remaining 25%, and the entire mxRNAseq dataset. 
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We first designed a composite classifier that uses a separate logistic regression classifier 
for each gene, and classifies each sample based on a composite of each gene’s classifications 
according a pre-provided rule set. Each component model was trained by inferring a training 
sample’s component gene class from the provided rule set. We additionally designed a variant of 
this composite model including correlated genes in each of the component models.  
We also used classification and regression trees24, as they provide a simple to interpret 
structure similar to the clinical algorithm. A decision tree was trained using a maximum tree 
depth of 3 nodes, and a minimum sample split of 5. 
RESULTS 
 Given the foundational importance of classification to kidney tumor management, we 
first sought to assess the utility of our mxRNAseq panel for diagnosis of common tumor 
subtypes. In total, we generated mxRNAseq profiles for 146 informative clinical FFPE samples 
using our panel of 122 target genes. Unsupervised hierarchical clustering of both gene targets 
and samples is shown in Figure 3. Cell-cycle/proliferation targets clustered closely, indicating 
the ability of the assay to robustly detect a variety of proliferation signals. Targets indicative of 
immune-oncology response, such as CD8A, GZMA, CTLA4, FOXP3, and others, also showed 
strong clustering, consistent with the ability of the assay to detect immune infiltration. For 
example, CD8A – a marker of cytotoxic T lymphocytes clustered directly next to GZMA – a 
cytotoxic T lymphocyte protease.25 Samples clustered primarily by cell-cycle/proliferation 
(unsurprising given the number of related transcripts included in the panel), with highly 
proliferative Urothelial Carcinoma and Clear Cell RCC separating from most other samples. 
Within the proliferative sample cluster, Urothelial Carcinoma strongly separated from other 
subtypes, driven predominantly by urothelial markers PAX8 and TP63. 
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Figure 3: Unsupervised hierarchical clustering of samples and gene targets sequenced on 
the 122 gene targeted assay. After normalization, genes were centered by their medians, and 
outlier values were bounded between -5 and 5. Left panel shows all samples, while right shows 
only the most predominant subtypes.  
 
CCP Scores 
Using methodology previously described3, we calculated a derived Cell Cycle Progression 
(mxCCP)15 prognostic score for all samples, shown in Figure 4 with its composite genes. 
Urothelial Carcinoma samples showed the highest scores, with Clear Cell RCC samples also 
trending higher than others, as expected given their clustering behavior. Of note, some samples, 
for example KI-123, show high mxCCP scores while only showing high expression for a 
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minority of proliferation targets, supporting the role of multi-gene assays in measuring general 
proliferation activity.  
Figure 4: Heatmap of 31 genes that make up the cell cycle progression score. The derived 
score was calculated as previously described and was centered and scaled by all samples in this 
cohort to have unit variance and mean. Samples are ordered by score from left (least 
proliferative) to right (most proliferative). Highly proliferative Urothelial Carcinoma uniformly 
showed the highest scores, while Chromophobe RCC and Papillary RCC predominantly showed 
low-proliferation scores.  
 
 Although limited in sample number and not the focus of this initial assessment, we did not find 
significant differences in mxCCP scores across nuclear (Furhman) grades in Clear Cell RCC, as 
shown in Figure 5. 
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Figure 5: Heatmap and boxplot of Clear Cell RCC samples, annotated with Fuhrman 
Nuclear Grade. mxCCP score is not predictive of Fuhrman Grade, indicating other processes 
play a role in poor nuclear differentiation measured by this score. 
 
Subtype Multivariate Modeling 
As diagnosis of renal tumors often involves a battery of immunostains, even for 
pathologists with extensive genitourinary pathology experience, there is the potential to augment 
or replace an immunohistochemistry (IHC) based approach with mxRNAseq, given this 
platform’s ability to measure many targets simultaneously at a low cost even on very small 
biopsy samples. Hence, we attempted to characterize the panel’s ability to accurately classify 
primary renal tumor subtype using two approaches. First, we looked at whether measuring the 
RNA expression of canonical IHC markers2 could yield an accurate classifier on their own. 
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Secondly, we sought to see whether the inclusion of other potentially relevant markers included 
on the targeted panel might allow for better classification. 
To assess whether markers traditionally used in IHC diagnostics could provide an 
accurate diagnosis at the RNA level, we first attempted to replicate the decision rubric used to 
evaluate canonical IHC antigens2 (Figure 1). This model performed relatively well in our 
withheld TCGA testing data set with ROC curves with AUC values shown in Figure 6 but had 
difficulty generalizing to the mxRNAseq data. Of note, because each gene’s positive/negative 
status is predicted independently of one another, this can produce a pattern that does not match 
any trained subtype. This occurred in 90 TCGA testing samples, and 32 mxRNAseq validation 
samples, and were always scored as incorrect for performance validation purposes.  
 
Figure 6: Receiver operating characteristic(ROC) curves measuring the performance of 
RNAseq replicated IHC decision tree. Separate logistic regression models were trained for 
each gene involved in IHC-based subtyping, and their predictions for each sample were 
combined according to the IHC decision tree to yield a predicted subtype. Left panel shows 
performance on TCGA testing data, right on mxRNAseq validation.  
 
Thus, we next assessed whether statistical learning algorithms could recapitulate the 
algorithm currently used in clinical practice. We trained a multinomial logistic regression model 
on just expression of targets measured in clinical IHC-based analysis. The directionality 
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(positive/negative) of the trained coefficients (Table 1) was mostly concordant with the 
directionality used to subtype tumors using IHC. For example, CA9 and AMACR are both 
negative in Chromophobe RCC and show negative coefficients for Chromophobe RCC. This 
approach performed well, with performance gains in both the TCGA and mxRNAseq datasets 
(Figure 7).  Of note, Papillary RCC is the only subtype in which this not the case; the 
directionality of its coefficients do not match the known marker status for TP63 and AMACR.  
 
Chromophobe RCC Clear Cell RCC Papillary RCC Urothelial Carcinoma 
TP63 -1.75828 -3.44541 0.006539 1.405575 
PAX8 -0.04699 -0.81781 2.593376 -4.37143 
KRT7 -0.36471 -2.34942 -0.70006 1.990789 
KIT 0.957877 0.078807 -0.57821 -1.09337 
CA9 -2.27608 2.797833 -1.99381 -1.71269 
AMACR -1.12483 -0.13133 0.769411 -0.94736 
Table 1 – Multinomial logistic regression coefficients  
 
Figure 7: ROC curves measuring the performance of multinomial logistic regression. A 
multinomial logistic regression models was trained on markers used for IHC analysis. Left panel 
shows performance on TCGA testing data, right on mxRNAseq validation.  
 
We also attempted to use non-linear models, such as classification and regression trees. 
These models have the benefit of generating a hierarchical structure similar to ones used in 
clinical practice, and can capture non-linear relationships that don’t appear in the linear models. 
This model recapitulated the IHC decision tree, while eliminating redundant markers.  
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Figure 8: Classification tree and ROC curve performance derived from RNAseq data. 
Panel A: A learned classification tree from RNAseq analysis of only IHC targets. Urothelial 
Carcinoma samples are classified solely on PAX8 expression. CA9 expression determined 
whether a non-UC sample was Clear Cell or not, with KIT expression being the final determinant 
of the Papillary RCC vs. Chromophore RCC subtype.  B: ROC Curves of model performance. 
Model shows high performance on TCGA data, but generalizes poorly to Papillary RCC in the 
mxRNAseq cohort.  
 
We next attempted to determine whether analyzing the entire panel (outside of the 
already known IHC genes) might provide additional insight. We trained a random forest 
classifier, and adaptive boosted trees classifier on the entire panel, and while it performed well 
on the TCGA data, it generalized poorly to the mxRNAseq validation data, especially for 
Chromophobe and Papillary RCC samples (Figure 9). One explanation for this discrepancy may 
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be proliferation - proliferation markers including UBE2C, KIF11, and RAD51 make up 3 of the 
top genes in the model by gini score, and could be driving classification behaviors on 
proliferation instead of other biology if there are proliferation differences between the cohorts.  
Figure 9: ROC curves of random forest model trained on all targets. Models have strong 
performance within the TCGA dataset, but generalize poorly to the mxRNA dataset outside of 
Urothelial Carcinoma.  
 
Unclassified RCCs 
A major problem in the management of RCC are tumors that don’t meet the classification 
criteria for any particular subtype, and are therefore deemed “unclassified”. Such diagnosis is 
usually made only after extensive IHC, resulting in a large cost for a diagnosis with little utility 
to the urologist/medical oncologist. We thus sought to apply our models (trained on classified 
samples) to these unclassified samples, to see if these models could inform on their potential 
underlying phenotype. Of the 12 Unclassified RCCs in our cohort, the single gene models only 
mapped one to the known subtypes – one with Oncocytic features to Chromophobe RCC. The 
remaining 11 samples had expression patterns that did not match any of the trained subtypes.  
Using the well performing multinomial model, we calculated the probability of an 
unclassified sample belonging to each trained subtype. 6/8 samples with Sarcomatoid features 
were most likely to be Clear Cell RCC, with the remaining 2 most likely Papillary RCC. One 
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sample with both Papillary and Sacromatoid features was mostly Clear Cell RCC (77.4%), but 
had a strong Papillary RCC component (22.4%). While this analysis can’t definitively classify 
these samples, it suggests that RNAseq may enable increased resolution. 
 
DISCUSSION 
 Our group developed a targeted mxRNAseq panel for the comprehensive profiling of 
kidney tumors. The panel shows the robust ability to differentiate various kidney cancer 
subtypes, both unsupervised (as in without any priors as shown in Figure 3) and supervised (as 
in the various models shown in Figures 6-9). In addition, we show that a mxRNAseq derived 
version of the Cell Cycle Progression score is capable of assessing the underlying proliferation of 
the tumor. We also demonstrate the potential utility of using RNAseq based methods to better 
characterize unclassified disease through increased molecular resolution.  
 Our approach has several limitations. The major motivator of this study is to use RNA-
based technologies for simpler and higher-throughput classification and characterization of 
kidney cancers. However, this approach relies on mRNA expression levels of protein targets to 
be accurate proxies for protein expression. In this case, we show that they are for the purposes of 
classifying the most common subtypes in our cohort, but the variety of gene regulatory 
mechanism, including micro-RNA (miRNA) and epigenetic regulation may preclude this 
approach from working with all subtypes, or different driving molecular alterations. 
 In addition, the use of TCGA data to train supervised models adds potential bias to our 
models. We used TCGA data homogenized with our mxRNAseq data to provide substantial 
training examples for model parameter estimation. However, while our homogenization was 
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seemingly effective as shown in Figure 2, there are artifacts associated with comparing full 
transcriptome sequenced via a poly-A selection method with targeted amplicons that may not 
been removed by a standard unit mean and variance homogenization. Additionally, several 
studies have demonstrated the misclassification of tumors in TCGA data26, potentially 
confounding our ability to accurately train model parameters.  
 The targeted mxRNAseq approach we use poses its own limitations. While targeted 
mxRNAseq holds promise for its ability to characterize degraded samples and lower cost than 
traditional transcriptome RNAseq, it also accordingly provides less data than a full transcriptome 
might. For subtyping or clinical purposes described here, that poses little problem, as that mostly 
is occurring on a constrained set of genes, However, for characterizations of unclassified RCCs, 
this technique doesn’t fully characterize the expression activity of these cancers. While we have 
shown that the additional range of detection afforded by RNAseq technologies may allow for 
deconvolution of known subtypes within unclassified tumors, our panel does not enable the 
characterization of targets not known to be involved in this cancer. However, future studies 
involving deep full-transcriptome sequencing of unclassified RCCs may be beneficial to 
understanding their composition and relationship to known subtypes.  
 Integration of RNAseq data in this study and DNA somatic single nucleotide and copy 
number variants may also provide important information for proper characterization of these 
cancers, as the Tomlins laboratory has shown in other tumor types.3,27 While mRNA expression 
provides valuable information about the expression state of the tissue, it doesn’t encode the 
driving mutation(s) responsible for the malignancy. 
 Importantly, targeted mxRNAseq provides opportunities to simplify and reduce the costs 
of cancer research. Here we have shown that a kidney cancer specific mxRNAseq assay has the 
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ability to accurately classify major subtypes using markers clinically used in protein analysis, 
and the potential for the assay to be used to characterize multi-target phenotypes, such as cell 
cycle/proliferation. 
ACKNOWLEDGEMENTS 
Thank you to the entire Tomlins Lab and collaborators for your support over the past few years, 
especially Komal Kunder and Aaron Udager for sequencing the samples in this study, Dan 
Hovelson for teaching me basically all I know about bioinformatics analysis, and Dr. Scott 
Tomlins for giving me the freedom to explore my interests and grow my skillset.  
Thank you to my family for your love and support.  
  
Kaplan 20 
 
REFERENCES 
1.  Murcia O, Juárez M, Rodríguez-Soler M, et al. Colorectal cancer molecular classification 
using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and 
response to chemotherapy. PLoS ONE. 2018;13(9):e0203051. 
doi:10.1371/journal.pone.0203051 
2.  Reuter VE, Argani P, Zhou M, Delahunt B, Members of the ISUP Immunohistochemistry in 
Diagnostic Urologic Pathology Group. Best practices recommendations in the application of 
immunohistochemistry in the kidney tumors: report from the International Society of 
Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e35-49. 
doi:10.1097/PAS.0000000000000258 
3.  Salami SS, Hovelson DH, Kaplan JB, et al. Transcriptomic heterogeneity in multifocal 
prostate cancer. JCI Insight. 2018;3(21). doi:10.1172/jci.insight.123468 
4.  Cieslik M, Chugh R, Wu Y-M, et al. The use of exome capture RNA-seq for highly degraded 
RNA with application to clinical cancer sequencing. Genome Res. 2015;25(9):1372-1381. 
doi:10.1101/gr.189621.115 
5.  Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Oncotype DX prostate 
cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC 
Genomics. 2013;14:690. doi:10.1186/1471-2164-14-690 
6.  Thermo Fisher Scientific. Targeted RNA Sequencing by Ion Torrent Next-Generation 
Sequencing. https://www.thermofisher.com/us/en/home/life-science/sequencing/rna-
sequencing/targeted-rna-sequencing-ion-torrent-next-generation-sequencing.html. Accessed 
March 14, 2019. 
7.  Illumina. TruSeq Stranded mRNA | Sequence mRNA samples. 
https://www.illumina.com/products/by-type/sequencing-kits/library-prep-kits/truseq-
stranded-mrna.html. Accessed March 14, 2019. 
8.  Langner C, Ratschek M, Tsybrovskyy O, Schips L, Zigeuner R. P63 Immunoreactivity 
Distinguishes Upper Urinary Tract Transitional-cell Carcinoma and Renal-cell Carcinoma 
Even in Poorly Differentiated Tumors. J Histochem Cytochem. 2003;51(8):1097-1099. 
doi:10.1177/002215540305100813 
9.  Ordóñez NG. Value of PAX 8 Immunostaining in Tumor Diagnosis: A Review and Update. 
Advances in Anatomic Pathology. 2012;19(3):140. doi:10.1097/PAP.0b013e318253465d 
10.  Genega EM, Ghebremichael M, Najarian R, et al. Carbonic anhydrase IX expression in renal 
neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010;134(6):873-879. 
doi:10.1309/AJCPPPR57HNJMSLZ 
Kaplan 21 
 
11.  Liao S-Y, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 
Protein As a Reliable Diagnostic Biomarker of Clear Cell Carcinoma of the Kidney. Cancer 
Res. 1997;57(14):2827-2831. 
12.  Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S. Overexpression of KIT 
in chromophobe renal cell carcinoma. Oncogene. 2003;22(6):847-852. 
doi:10.1038/sj.onc.1206153 
13.  Wang H-Y, Mills S. KIT and RCC Are Useful in Distinguishing Chromophobe Renal Cell 
Carcinoma From the Granular Variant of Clear Cell Renal Cell Carcinoma. The American 
Journal of Surgical Pathology. 2005;29(5):640-646. 
doi:10.1097/01.pas.0000157943.33903.92 
14.  Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature 
derived from cell cycle proliferation genes for recurrence and death from prostate cancer: A 
retrospective study in two cohorts. Lancet Oncol. 2011;12(3):245-255. doi:10.1016/S1470-
2045(10)70295-3 
15.  Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature 
for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 
2012;106(6):1095-1099. doi:10.1038/bjc.2012.39 
16.  Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. 
Science. 2017;357(6352). doi:10.1126/science.aan2507 
17.  Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine Learning in Python. 
Journal of Machine Learning Research. 2011;12:2825–2830. 
18.  Davis CF, Ricketts CJ, Wang M, et al. The somatic genomic landscape of chromophobe 
renal cell carcinoma. Cancer Cell. 2014;26(3):319-330. doi:10.1016/j.ccr.2014.07.014 
19.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. New 
England Journal of Medicine. 2016;374(2):135-145. doi:10.1056/NEJMoa1505917 
20.  Cancer Genome Atlas Research Network. Comprehensive molecular characterization of 
clear cell renal cell carcinoma. Nature. 2013;499(7456):43-49. doi:10.1038/nature12222 
21.  Cancer Genome Atlas Research Network. Comprehensive molecular characterization of 
urothelial bladder carcinoma. Nature. 2014;507(7492):315-322. doi:10.1038/nature12965 
22.  Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for 
exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404. 
doi:10.1158/2159-8290.CD-12-0095 
23.  Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and 
clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. 
doi:10.1126/scisignal.2004088 
Kaplan 22 
 
24.  Breiman L, Friedman J., Olshen RA, Stone CJ. Classification and Regression Trees. 
25.  Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and Genetic Properties of 
Tumors Associated with Local Immune Cytolytic Activity. Cell. 2015;160(1):48-61. 
doi:10.1016/j.cell.2014.12.033 
26.  Favazza L, Chitale DA, Barod R, et al. Renal cell tumors with clear cell histology and intact 
VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas 
database. Mod Pathol. 2017;30(11):1603-1612. doi:10.1038/modpathol.2017.72 
27.  Hovelson DH, Udager AM, McDaniel AS, et al. Targeted DNA and RNA Sequencing of 
Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and 
Transcriptomic Events and Unique Therapeutic Implications. Eur Urol. 2018;74(6):741-753. 
doi:10.1016/j.eururo.2018.06.047 
 
